Moran Wealth Management LLC lowered its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 3.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 212,218 shares of the company

Mosaic Family Wealth Partners LLC raised its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 154.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,904 shares of the company

Mitsubishi UFJ Trust & Banking Corp raised its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 8.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,727,562 shares of the company

ANTIPODES PARTNERS Ltd decreased its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 23.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,097,509 shares of the company

Merck & Co. stock has pushed to a new 52-week high in August 2026 as investors digest positive Phase

Midwest Trust Co decreased its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 1.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 738,473 shares of the company

KBC Group NV reduced its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 7.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,131,286 shares of the company

HighTower Advisors LLC grew its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 1.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,679,920 shares of the company

USA Financial Formulas purchased a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) during the first quarter, according to its most recent filing with the SEC. The fund purchased 7,410 shares of the company

Janney Montgomery Scott LLC lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 1.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,655,632 shares of the company

Fifth Third Bancorp reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,500,619 shares of the company

Donaldson Capital Management LLC grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 1.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 798,673 shares of the company

Delivers cutting-edge commentary on important legal issues affecting health care and life sciences institutions.

Principal Financial Group Inc. increased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 0.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,751,479 shares of the company

RHL Group LLC cut its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 97.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 500 shares of the company

TD Asset Management Inc grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,334,726 shares of the company

Heritage Investors Management Corp lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 4.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 316,592 shares of the company

Advisors Management Group Inc. ADV redujo su participación en acciones de Merck & Co., Inc. (NYSE:MRK - Free Report) en un 95,0% en el segundo trimestre, según su presentación 13F más reciente ante la SEC. El fondo poseía 2.579 acciones de la empresa.

Wall Street Zen elevó las acciones de Merck & Co., Inc. de una calificación de "mantener" a una calificación de "comprar" en un informe de investigación del sábado.

Las acciones de Merck & Co. cotizan justo por debajo de un nuevo máximo histórico a finales de agosto de 2026 después de la fase 3 mela